Merck VP & Chief Licensing Officer Barbara Yanni: An Interview With “The Pink Sheet” DAILY

Merck is bolstering its pipeline through acquisitions and licensing deals, many in biotech. The drug maker evaluates 6,000 opportunities per year and signed 44 transactions in 2005.